Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04053036 · ClinicalTrials.gov registry record · Early Phase 1
Effects of Drugs on Responses to Brain and Emotional Processes
A Early Phase 1 study of Healthy and Autism Spectrum Disorder, sponsored by University of Chicago.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 22
- Enrollment target
- 1
- Study location
NCT04053036: Completed Early Phase 1 study of Healthy and Autism Spectrum Disorder, sponsored by University of Chicago.
NCT04053036 is a Early Phase 1 study of Healthy and Autism Spectrum Disorder that has completed, run by University of Chicago. The registered enrollment target is 22 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04053036, a Early Phase 1 study of Healthy and Autism Spectrum Disorder, has completed, sponsored by University of Chicago.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 22 participants
- Enrollment target
- 1
- Study location
Study Summary
To study the effects of a psychostimulant on responses to affective touch in individuals with a range of autistic traits
Primary Outcome
Participants will complete an affective touch task during which time they will rate pleasantness of touch on a scale of -10 to +10 using an analog scale. Higher ratings indicate greater pleasantness.
Conditions Studied
Interventions
- DRUG Placebo oral tablet
- DRUG MDMA
Study Locations (1)
Illinois
- University of Chicago - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2019-08-08 |
| Est. Completion | 2021-04-12 |
| Phase | Early Phase 1 |
What the finished NCT04053036 record still lists
NCT04053036 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (97% lower).
The record links to 2 conditions, with Healthy appearing as the primary indexed condition, and to 2 interventions - of which Placebo oral tablet is the first listed.
NCT04053036 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT04053036 about?
NCT04053036 is a clinical study titled "Effects of Drugs on Responses to Brain and Emotional Processes". To study the effects of a psychostimulant on responses to affective touch in individuals with a range of autistic traits
What is the current status of trial NCT04053036?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 22 participants. The study started on 2019-08-08. Estimated completion is 2021-04-12.
What conditions does trial NCT04053036 study?
This clinical trial studies the following conditions: Healthy, Autism Spectrum Disorder.
What interventions are being tested in trial NCT04053036?
The interventions under investigation include: Placebo oral tablet (DRUG), MDMA (DRUG).
Who is sponsoring clinical trial NCT04053036?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04053036 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04053036's enrollment target sits among peer trials
22 844th of 1090 higher than 235 of 1,090 other Healthy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Healthy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Mapping Auricular Vagus Nerve Circuitry
RECRUITING · Early Phase 1
-
Saccharomyces Boulardii CNCM I-745 on Intestinal Barrier Function
RECRUITING · Early Phase 1
-
SV2A Density Cannabis Use Disorder
RECRUITING · Early Phase 1
-
CBD-Microglia PET Study
RECRUITING · Early Phase 1
-
Sex Disparities in Hypoxic Vasodilation and Impact of Obesity
RECRUITING · Early Phase 1
-
Positron Emission Tomography (PET) Contrast Agent Kinetics and Safety: [18F]-Fluoromannitol
RECRUITING · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02508038 · 22 participants · Phase 1
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- NCT03099356 · 22 participants · Phase 2
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
- NCT03676647 · 22 participants
Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules
- NCT04569591 · 22 participants · NA
DDAVP for Pituitary Adenoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI